Kiromic Biopharma Inc (KRBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) has a cash flow conversion efficiency ratio of 0.290x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.65 Million) by net assets ($-12.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Kiromic Biopharma Inc for the company's overall valuation and market capitalisation.
Kiromic Biopharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kiromic Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiromic Biopharma Inc ranked by their cash flow conversion efficiency. See KRBP cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TRELLUS HEALTH LS -0006
F:85Q
|
N/A |
|
Gangotri Textiles Limited
NSE:GANGOTRI
|
0.000x |
|
Rua Life Sciences PLC
LSE:RUA
|
0.004x |
|
UMT United Mobility Technology AG
XETRA:UMDK
|
-0.046x |
|
Inspiration Healthcare Group PLC
LSE:IHC
|
0.222x |
|
Springer Nature AG & Co KGaA
XETRA:SPG
|
N/A |
|
TEVANO SYSTEMS HLDGS INC.
F:7RBA
|
N/A |
|
Eden Research plc
LSE:EDEN
|
-0.048x |
Annual Cash Flow Conversion Efficiency for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kiromic Biopharma Inc from 2018 to 2024. View current stock price of Kiromic Biopharma Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.59 Million | $-19.46 Million | 1.546x | -33.57% |
| 2023-12-31 | $-9.12 Million | $-21.23 Million | 2.327x | -43.41% |
| 2022-12-31 | $-5.77 Million | $-23.75 Million | 4.112x | +652.82% |
| 2021-12-31 | $27.32 Million | $-20.32 Million | -0.744x | -37.95% |
| 2020-12-31 | $11.36 Million | $-6.13 Million | -0.539x | +63.38% |
| 2019-12-31 | $1.98 Million | $-2.91 Million | -1.472x | +81.86% |
| 2018-12-31 | $265.30K | $-2.15 Million | -8.115x | -- |
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more